Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Nov 22;379(21):2086.
doi: 10.1056/NEJMc1810994.

Oligonucleotide Drugs for Transthyretin Amyloidosis

Joel N Buxbaum  1
Affiliations
Comment

Oligonucleotide Drugs for Transthyretin Amyloidosis

Joel N Buxbaum. N Engl J Med. .
No abstract available

PubMed Disclaimer

Comment on

  • Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
    Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Benson MD, et al. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793. N Engl J Med. 2018. PMID: 29972757 Clinical Trial.
  • Oligonucleotide Drugs for Transthyretin Amyloidosis.
    Berk JL, Barroso FA, Coelho T. Berk JL, et al. N Engl J Med. 2018 Nov 22;379(21):2085-6. doi: 10.1056/NEJMc1810994. N Engl J Med. 2018. PMID: 30484623 No abstract available.
  • Oligonucleotide Drugs for Transthyretin Amyloidosis.
    Adams D, Hawkins PN, Polydefkis M. Adams D, et al. N Engl J Med. 2018 Nov 22;379(21):2086. doi: 10.1056/NEJMc1810994. N Engl J Med. 2018. PMID: 30484624 No abstract available.

Substances

Supplementary concepts